Clinical Trial Update: A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV [Phase 3]

View source ↗

Summary

Phase 3 randomized, double-blind, multicenter, sham-controlled study assessing the safety and efficacy of Conbercept in patients with myopic choroidal neovascul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Degenerative Myopia

Drugs mentioned

• Conbercept (conbercept)

Snippet

Sponsor: Chengdu Kanghong Biotech Co., Ltd. | Conditions: Choroid Neovascularization Secondary to Degenerative Myopia | Phase 3 | Status: UNKNOWN